RTTNews | Jan 18, 2022 10:28AM EST

10:27 Tuesday, January 18, 2022 (RTTNews.com) - Shares of Mainz Biomed B.V. (MYNZ) are gaining over 22% on Tuesday morning, as the molecular genetics diagnostic company continues its rally.

MYNZ is currently trading at $25.47, up $4.60 or 22.02%, on the Nasdaq. For the year to date period, the stock has gained nearly 145%.

Mainz Biomed, a molecular genetics cancer diagnostic company, develops in-vitro diagnostic tests for clinical diagnostics in the area of human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a stool-based screening test for the detection of pancreatic cancer; GenoStrip, an early-stage molecular lateral-flow test; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.

Read the original article on RTTNews ( https://www.rttnews.com/3255663/mainz-biomed-rally-continues-stock-up-22.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2022 RTTNews.com All Rights Reserved